Training activity information
Details
Perform and interpret the appropriate techniques for the investigation of haemolytic disease of the Fetus and newborn
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- Local SOPs
- Guidelines and standards, including EQA and IQC
- Maintenance and basic troubleshooting
- Reference intervals
- Limitations of the methods
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What are the underlying mechanisms of haemolytic disease of the fetus and newborn (HDFN), and what maternal and fetal/neonatal laboratory tests are involved in its investigation (e.g., maternal antibody screening and identification, fetal blood grouping, direct antiglobulin test)?
- How will you interpret the results of these tests to assess the risk and severity of HDFN?
- What is the role of anti-D prophylaxis in the prevention of HDFN, and how is this monitored in the laboratory?
- Consider the specific insights you hope to gain, such as understanding the importance of antenatal and postnatal testing in preventing and managing HDFN.
- Reflect on your current knowledge of HDFN and its laboratory investigation, and how this training activity will develop your skills in this specialised area of transfusion science.
- Discuss with your training officer the specific serological tests and protocols used in your laboratory for investigating HDFN.
- Review the principles and interpretation of these tests, including the significance of maternal antibodies and the DAT result in the newborn.
- Think about potential challenges, such as interpreting complex antibody profiles or understanding the clinical implications of different findings, and consider how you might address them (e.g., reviewing guidelines, discussing with senior colleagues or the fetal medicine team).
In action
- As you perform tests related to haemolytic disease of the fetus and newborn (HDFN) (e.g., maternal antibody screen, fetal blood group, DAT on newborn sample), what specific antibodies or antigens are you prioritising in your investigation?
- What observations are you making during the testing process (e.g., strength of DAT reaction, specificities of maternal antibodies)?
- How confident are you in your technical abilities in this complex area? What challenges are you facing with these investigations?
- Are there additional tests that might be necessary based on initial results? Do you need to consult specialist HDFN protocols or reference laboratories?
- Are you following the correct procedures for these specialised serological investigations?
- During interpretation of the results, what maternal antibodies are clinically significant for HDFN? What is the likely blood group of the fetus/newborn?
- What is the significance of the DAT result?
- How certain are you about your interpretation of the risk of HDFN?
- What unexpected serological findings are present? What are you learning about the interpretation of HDFN investigations and the prediction of disease severity?
- Are there alternative serological explanations? Should you discuss these findings with the obstetric team?
On action
- Identify the specific techniques you performed and interpreted for investigating Haemolytic Disease of the Fetus and New-born (HDFN) (e.g., antibody identification, titration, fetal blood group).
- What were the key steps for each? What were the expected results in different HDFN scenarios?
- What were the significant findings in the case you investigated?
- Were there any technical challenges or unexpected results encountered during the investigation?
- How did you interpret the serological findings in the context of potential risk to the fetus or new-born?
- What new skills or knowledge did you acquire or improve related to the investigation of HDFN?
- Did you encounter any complex serological investigations?
- What did you learn from these?
- How did this activity enhance your understanding of the serological principles and their clinical significance in HDFN?
- What will you take from the experience moving forward?
- What specific areas within the investigation of HDFN have you identified for further learning and development?
- How will you apply the knowledge and skills gained from this activity to future investigations related to HDFN?
- What specific actions will you undertake to enhance your skills and knowledge in this area?
- What resources or support do you think would be beneficial for your ongoing development in this specialised field?
Beyond action
- Reflect on your engagement with the techniques used to investigate Haemolytic Disease of the Fetus and New-born (HDFN) (e.g., maternal antibody screening and identification, fetal blood sampling, direct antiglobulin test on the new-born). Has your understanding of the maternal-fetal interactions, the potential severity of HDFN, and the interpretation of the relevant serological tests evolved with further learning and exposure to relevant cases?
- Compare your reflections on this training activity with those from other training activities involving red cell serology or transfusion reactions. What are the specific considerations and challenges when dealing with serological investigations in the context of pregnancy and the new-born?
- Review your original reflections on this training activity. Have you gained a greater appreciation for the role of the laboratory in the management of HDFN and the importance of timely and accurate results?
- Discuss the complexities of HDFN investigations and management with colleagues, particularly those with experience in antenatal and neonatal serology. Has this provided any new insights into best practices?
- How has your learning from this training activity influenced your awareness of the clinical significance of maternal red cell antibodies and the importance of appropriate testing and monitoring?
- Can you identify situations in your current practice where your knowledge from this training activity has helped you understand the rationale behind specific serological tests performed in pregnant women or new-borns?
- What transferable skills, such as meticulous attention to detail in complex serological investigations, understanding the clinical context of laboratory results, or effective communication with clinical colleagues, did you develop through this training activity? How will these skills be essential in your future practice?
- Based on your reflection, what specific aspects of HDFN investigation and management (e.g., understanding complex antibody interactions, the role of molecular testing in RhD typing) do you aim to develop further?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 |
Outcome
Select techniques for the investigation of clinical presentations in haematology, haemostasis and transfusion science and medicine. |
| # 2 |
Outcome
Perform the laboratory techniques required for the investigation of clinical presentations in haematology, haemostasis and transfusion science and medicine. |
| # 3 |
Outcome
Interpret the results of the laboratory investigations for cases including red and white cell disorders and haemostatic and platelet disorders, haematological malignancy and transfusion serology. |
| # 4 |
Outcome
Describe the limitations of techniques applied in the investigation of clinical presentations in haematology, haemostasis and transfusion science. |
| # 5 |
Outcome
Apply the principles of internal quality control and external quality assessment and draw conclusions about assay performance. |
| # 6 |
Outcome
Demonstrate appropriate communication skills to present the results of investigations and cases clearly to healthcare professional colleagues. |